세계의 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트별(서비스, 데이터세트), 최종사용자별(의료비 지불자, 의료 제공자), 애플리케이션별 시장 규모, 점유율 및 동향 분석, 부문별 예측(2021-2028년)

Real World Evidence Solutions Market Growth & Trends:

The global real world evidence solutions market size is expected to reach USD 78.80 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.1% from 2022 to 2030. The key factors driving the real world evidence (RWE) solutions market include favorable government regulations and a shift from volume to value-based care. Furthermore, the increasing prevalence of chronic disorders is anticipated to positively influence market growth.

During the pandemic, companies in the RWE solutions market diverted their focus on providing solutions for curbing the spread of COVID-19. For instance, IBM collaborated with Salesforce for building digital health passes, which incorporated data such as vaccine status, temperature checks, and COVID-19 test results for helping organizations to reopen safely. It also partnered with ServiceNow on Watson AIOps for supporting it to continue its leadership in transformative artificial intelligence by helping clients automate IT operations and reduce risks.

According to PerkinElmer, real world evidence solutions offer around USD 300 to 500 Billion in top-down opportunity for the U.S. healthcare industry alone. In addition, many life science companies are witnessing ad hoc value from selected RWE case studies and demonstrating around USD 100 million of bottom-up impact. Therefore, if a company captures USD 1 billion in real world evidence value, it ultimately creates more than USD tens of billions in terms of healthcare improvements. This is anticipated to boost the market growth.

The adoption and usage of RWE solutions are higher in developed markets of North America and Europe owing to supportive initiatives by legal, government, and other regulatory bodies. For instance, in October 2021, FDA selected Aetion Evidence Platform to use RWE to analyze COVID-19 interventions and further regulatory science and innovation. Initiatives by regulatory agencies are supporting the expansion of RWE from post-market safety monitoring to other applications, such as for clinical trial design and observational studies and to substantiate coverage decisions.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in August 2021, Syneos Health partnered with Aetion for offering RWE solutions for advanced drug development and commercialization. This partnership brought together Syneos Health's proprietary data collection research solutions and Aetion's Evidence platform, AEP, for generating evidence through patient data curation and real world data.

Real World Evidence Solutions Market Report Highlights:

• Favorable government initiatives and a shift from volume to value-based care are expected to boost the market growth

• The services component segment led the market in 2021 owing to its increasing demand over the forecast period

• The drug development and approvals application segment dominated the market in 2021 owing to the rising adoption of RWE solutions in pharmaceutical companies for this application

• The healthcare payers end-user segment is anticipated to expand at the fastest CAGR over the forecast period owing to the increasing awareness among payers regarding drug and medical device safety

• North America led the global market in 2021 with a revenue share of more than 40.0% owing to the presence of major players in the region

• Asia Pacific is expected to be the fastest-growing regional market from 2022 to 2030 owing to the presence of contract research organizations in the region

• The market is a fairly competitive market. For instance, in April 2021, Thermo Fisher Scientific announced that it is set to acquire PPD, Inc. for USD 47.50 per share

Table of Contents

Chapter 1 Research Methodology & Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Component
  • 1.1.2 Application
  • 1.1.3 End-User
  • 1.1.4 Region
  • 1.1.5 Estimates and forecast timeline
• 1.2 Research methodology
• 1.3 Information procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
    • 1.3.5.1 Data for primary interviews in North America
    • 1.3.5.2 Data for primary interviews in Europe
    • 1.3.5.3 Data for primary interviews in Asia Pacific
    • 1.3.5.4 Data for primary interviews in Latin America
    • 1.3.5.5 Data for primary interviews in Middle East & Africa
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity Flow Approach
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Segment Outlook
• 2.3 Competitive Insights

Chapter 3 Real world evidence (RWE) Solutions Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market outlook
  • 3.1.2 Ancillary market outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market driver analysis
    • 3.3.1.1 Favorable government regulations
    • 3.3.1.2 Shift from volume-to-value based care
  • 3.3.2 Market restraint analysis
    • 3.3.2.1 Lack of Standards
  • 3.3.3 Market Opportunity Analysis
  • 3.3.4 Market Challenges Analysis
• 3.4 Real world evidence (RWE) Solutions: Market Analysis Tools
  • 3.4.1 Industry analysis - Porter's
    • 3.4.1.1 Bargaining power of buyers:
    • 3.4.1.2 Bargaining power of suppliers:
    • 3.4.1.3 Competitive rivalry:
    • 3.4.1.4 Threat of new entrants:
    • 3.4.1.5 Threat of substitutes:
  • 3.4.2 PESTLE analysis
    • 3.4.2.1 Political landscape
    • 3.4.2.2 Environmental landscape
    • 3.4.2.3 Social landscape
    • 3.4.2.4 Technology landscape
    • 3.4.2.5 Legal landscape
    • 3.4.2.6 Economic landscape
• 3.5 Regulatory Framework
• 3.6 Pricing Model Analysis
  • 3.6.1 Pay Per Usage
  • 3.6.2 Pay Per Patient Record
  • 3.6.3 Annual Subscription

Chapter 4 Impact of COVID-19 on Real world evidence (RWE) Solutions Market

• 4.1 Disease Prevalence Analysis
• 4.2 Current and Future Impact Analysis
• 4.3 Impact of COVID-19 on Market Players
• 4.4 Opportunity Analysis

Chapter 5 Real world evidence (RWE) Solutions Market: Component Estimates and Forecasts to 2030

• 5.1 Definition and Scope
• 5.2 Component Type Market Share Analysis, 2021 & 2030
• 5.3 Segment Dashboard
• 5.4 Global Real world evidence (RWE) Solutions Market, by Component, 2017 to 2030
• 5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
  • 5.5.1 Services
    • 5.5.1.1 Services market, 2017 - 2030 (USD Million)
  • 5.5.2 Data Sets
    • 5.5.2.1 Data Sets market, 2017 - 2030 (USD Million)
    • 5.5.2.2 Clinical Settings Data
    • 5.5.2.2.1 Clinical Settings Data market, 2017 - 2030 (USD Million)
    • 5.5.2.3 Claims Data
    • 5.5.2.3.1 Claims Data market, 2017 - 2030 (USD Million)
    • 5.5.2.4 Pharmacy Data
    • 5.5.2.4.1 Pharmacy Data market, 2017 - 2030 (USD Million)
    • 5.5.2.5 Patient-Powered Data
    • 5.5.2.5.1 Patient-Powered Data market, 2017 - 2030 (USD Million)

Chapter 6 Real world evidence (RWE) Solutions Market: Application Estimates and Forecasts to 2030

• 6.1 Definition and Scope
• 6.2 Application Market Share Analysis, 2021 & 2030
• 6.3 Segment Dashboard
• 6.4 Global Real world evidence (RWE) Solutions Market, by Application, 2017 to 2030
• 6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
  • 6.5.1 Drug Development & Approvals
    • 6.5.1.1 Drug Development & Approvals market, 2017 - 2030 (USD Million)
  • 6.5.2 Medical Device Development & Approvals
    • 6.5.2.1 Medical Device Development & Approvals market, 2017 - 2030 (USD Million)
  • 6.5.3 Reimbursement/Coverage & Regulatory Decision Making
    • 6.5.3.1 Reimbursement/Coverage & Regulatory Decision Making market, 2017 - 2030 (USD Million)
  • 6.5.4 Post Market Safety & Adverse Events Monitoring
    • 6.5.4.1 Post Market Safety & Adverse Events Monitoring market, 2017 - 2030 (USD Million)

Chapter 7 Real world evidence (RWE) Solutions Market: End-User Estimates and Forecasts to 2030

• 7.1 Definition and Scope
• 7.2 End-user Market Share Analysis, 2021 & 2030
• 7.3 Segment Dashboard
• 7.4 Global Real world evidence (RWE) Solutions Market, by end-user, 2017 to 2030
• 7.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
  • 7.5.1 Pharmaceutical & Medical Device Companies
    • 7.5.1.1 Pharmaceutical & Medical Device Companies market, 2017 - 2030 (USD Million)
  • 7.5.2 Healthcare Payers
    • 7.5.2.1 Healthcare Payers market, 2017 - 2030 (USD Million)
  • 7.5.3 Healthcare Providers
    • 7.5.3.1 Healthcare Providers market, 2017 - 2030 (USD Million)
  • 7.5.4 Others
    • 7.5.4.1 Others market, 2017 - 2030 (USD Million)

Chapter 8 Real world evidence (RWE) Solutions Market: Regional Estimates & Trend Analysis, By Component, Application, End-User

• 8.1 Definition and Scope
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 North America
  • 8.3.1 North America Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.3.1.1 U.S.
    • 8.3.1.1.1 U.S. Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.3.1.2 Canada
    • 8.3.1.2.1 Canada Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
• 8.4 Europe
  • 8.4.1 Europe Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.4.1.1 U.K.
    • 8.4.1.1.1 U.K. Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.4.1.2 Germany
    • 8.4.1.2.1 Germany Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.4.1.3 France
    • 8.4.1.3.1 France Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.4.1.4 Italy
    • 8.4.1.4.1 Italy Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.4.1.5 Spain
    • 8.4.1.5.1 Spain Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
• 8.5 Asia Pacific
  • 8.5.1 Asia Pacific Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.5.1.1 Japan
    • 8.5.1.1.1 Japan Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.5.1.2 China
    • 8.5.1.2.1 China Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.5.1.3 India
    • 8.5.1.3.1 India Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.5.1.4 Australia
    • 8.5.1.4.1 Australia Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.5.1.5 South Korea
    • 8.5.1.5.1 South Korea Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1 Latin America Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.6.1.1 Brazil
    • 8.6.1.1.1 Brazil Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.6.1.2 Mexico
    • 8.6.1.2.1 Mexico Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.6.1.3 Argentina
    • 8.6.1.3.1 Argentina Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
• 8.7 MEA
  • 8.7.1 MEA Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.7.1.1 South Africa
    • 8.7.1.1.1 South Africa Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.7.1.2 Saudi Arabia
    • 8.7.1.2.1 Saudi Arabia Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)
    • 8.7.1.3 Israel
    • 8.7.1.3.1 Israel Real world evidence (RWE) Solutions market, 2017 - 2030 (USD Million)

Chapter 9 Real world evidence (RWE) Solutions Market: Competitive Analysis

• 9.1 Market Participation Categorization
• 9.2 Competitive Dashboard Analysis
• 9.3 Public Companies
  • 9.3.1 Company Market Share/Position Analysis
  • 9.3.2 Heat Map Analysis
• 9.4 Private Companies
  • 9.4.1 List of Key Companies

Chapter 10 Company Profiles

• 10.1 IQVIA
  • 10.1.1 Company Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Benchmarking
  • 10.1.4 Strategic Initiatives
• 10.2 IBM
  • 10.2.1 Company Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Benchmarking
  • 10.2.4 Strategic Initiatives
• 10.3 PPD Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Benchmarking
  • 10.3.4 Strategic Initiatives
• 10.4 Parexel International Corporation
  • 10.4.1 Company Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Benchmarking
  • 10.4.4 Strategic Initiatives
• 10.5 PerkinElmer Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Benchmarking
  • 10.5.4 Strategic Initiatives
• 10.6 Icon Plc
  • 10.6.1 Company Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Benchmarking
  • 10.6.4 Strategic Initiatives
• 10.7 Oracle
  • 10.7.1 Company Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Benchmarking
  • 10.7.4 Strategic Initiatives
• 10.8 Syneos Health
  • 10.8.1 Company Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Benchmarking
  • 10.8.4 Strategic Initiatives
• 10.9 Cegedim Health Data
  • 10.9.1 Company Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Benchmarking
  • 10.9.4 Strategic Initiatives
• 10.10 Medpace
  • 10.10.1 Company Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Benchmarking
  • 10.10.4 Strategic Initiatives